Key Quality Control Strategies in the Development of Recombinant Protein Drugs

Application Background of Recombinant Proteins in Biologics Development

Recombinant proteins are protein molecules expressed and purified in specific host cells using genetic recombination technology. They are widely used in the research and development of biologics for antibody drugs, cytokines, hormones, enzyme replacement therapies, and other directions. Compared with naturally extracted proteins, recombinant proteins have significant advantages in source controllability, batch-to-batch consistency, and safety design, making them an important foundation of modern biopharmaceutical manufacturing.

In the early drug discovery stage, researchers often require high-quality recombinant proteins as target antigens, activity standards, or functional validation materials. Their activity, purity, endotoxin levels, and post-translational modifications directly affect the reproducibility of screening experiments and the efficiency of subsequent process development.

Selection of Upstream Expression Systems

Common recombinant protein expression hosts include Escherichia coli, yeast, insect cells, and mammalian cells. The suitability of different hosts depends on the molecular weight, disulfide bonds, glycosylation requirements, and whether the target protein forms multimers. Prokaryotic systems offer rapid expression and lower cost, but generally have difficulty achieving complex post-translational modifications; eukaryotic systems more closely resemble native conformation, but involve longer culture periods and greater process complexity.

During the research and development stage, small-scale expression screening is generally performed based on the structural characteristics of the target protein, comparing soluble expression levels, correctly folded proportions, and activity recovery. Upstream construction also requires consideration of tag design, codon optimization, and promoter strength, as these factors affect subsequent purification difficulty and yield.

Purification and Impurity Control

Recombinant protein purification typically employs a combination of strategies including affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography, and gel filtration chromatography. Process design must balance target protein recovery and impurity removal capacity. Common impurities requiring control include host cell proteins, residual nucleic acids, endotoxins, aggregates, and degradation fragments. It is generally required to establish a multi-step orthogonal purification route and to test and set limit controls for residual levels of key impurities.

The buffer system, pH, and temperature during purification all affect protein stability. Therefore, accelerated stability studies and forced degradation studies are needed to understand protein degradation pathways and provide a basis for formulation development.

Critical Quality Attribute Analysis

The critical quality attributes of recombinant protein drugs typically include primary structure, higher-order structure, glycosylation modifications, charge heterogeneity, aggregate content, and biological activity. Analytical methods involve mass spectrometry, high-performance liquid chromatography, capillary electrophoresis, differential scanning calorimetry, and cell-based activity assays. Because minor differences may exist between batches, establishing robust analytical methods and quality standards is essential.

Overall, recombinant proteins in biologics development require establishing full-process quality awareness from molecular design, expression, and purification to analysis, in order to meet the technical requirements of pharmaceutical research and subsequent regulatory submissions.